TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06693661

Intervention type: OTHER
Group type: OTHER
Intervention: Kidney Health Coaching
Description: The intervention entails support from a KHC that includes:~* An initial rapport-building call~* Ongoing telephone support at least twice a month for six months~* Meeting the patient at all in-person clinic appointments~* Documenting interactions in the EMR using a customized platform~Telephone support begins with a social determinants of health (SDoH) screening tool to identify barriers and facilitators to CKD self-management and appointment adherence. This tool provides access to local resources based on the patient's ZIP code. Subsequent calls will follow up on resource usage, review CKD educational materials and treatment options, complete the Decision Aid for Renal Therapy tool, and facilitate communication through the patient portal. Each call will start with specific goals (e.g., review National Kidney Foundation CKD materials) and conclude with goals for the next session.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: ER Discharge (d/c): Patients may receive consultations and support from Care Management in the ER such as transportation or medication assistance. Follow-up by a social worker varies post-discharge.~Hospital d/c: All hospitalized patients are assessed by the care management team to identify psychosocial needs and begin discharge planning, which may include follow-up appointments and resources. High-risk patients receive additional follow-up from a care transitions coordinator for 30 days post-discharge.~Primary Care: Patients in primary care clinics have access to various support services. Those recently hospitalized or identified as high-risk receive care coordination from social workers. Internal referrals are managed by referral coordinators, while external referrals come from clinic staff. Discharge information is provided after visits.~Nephrology: There are no coordinated support services for chronic kidney disease (CKD) patients receiving nephrology care.
Study: NCT06435156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sodium-glucose Co-transporter inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT06693102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention targeting cancer-related cognitive impairments
Description: The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crossword and sudoku taks
Description: Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.
Study: NCT06692062

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
Study: NCT06693297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate loading of early placed implants
Description: Implants with active thread design will be used. The implants placed will be randomly allocated into either immediate loading or conventional loading group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate loading of early placed implants
Description: Implants with active thread design will be used. The implants placed will be randomly allocated into either immediate loading or conventional loading group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional loading of early placed implants
Description: Definitive loading of early placed implants upon successful osteointegration (after 8 weks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional loading of early placed implants
Description: Definitive loading of early placed implants upon successful osteointegration (after 8 weks)
Study: NCT06158841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous or IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral Tablet or IV Infusion
Study: NCT05334381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enhanced Treatment
Description: Follow up phone calls following discharge from the emergency department to confirm mental health treatment referral recommendations
Study: NCT05612295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBPP
Description: MBPP program consist of three fundamental principles (i.e., attention monitoring, acceptance, sport-specific rationale) and six performance-related core mental attributes including three behavioral and three neurocognitive components.~Each session will start with a brief homework discussion and recap of the preceding session, and instructors will deliver a topic-related brief story or group activity to participants, followed by a theoretical introduction and practice of mindfulness. Finally, at the end of each session, instructors will guide participant to discuss mindfulness applications related to specific sports performances. At the end of the session, participants will be assigned homework to increase the effectiveness of MBPP, and participants will be encouraged to practice daily for at least 10-15 min between the sessions.
Study: NCT05886738

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Obese and lean groups will fast for 48 hours, followed by a 3-hour refeeding period.
Study: NCT06352190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] SY-5007
Description: Carbon-14 labeled SY-5007
Study: NCT05337267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sintilimab (after the change)
Description: 0.3mg/kg，I.V.，single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab (before the change)
Description: 0.3mg/kg，I.V.，single dose
Study: NCT05782218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
Study: NCT06491381

Intervention type: PROCEDURE
Intervention: Cesarean delivery
Description: The cesarean section will begin with a Pfannenstiel incision above the pubic bone, followed by blunt dissection to separate tissue layers and retracting the rectus muscles for peritoneal cavity access. A transverse or vertical peritoneal incision will expose the uterus, and a transverse incision on the lower uterine segment will be made for delivery. The baby will be delivered, the umbilical cord clamped and cut, and the baby handed to the pediatric team. The placenta will be detached and delivered, and the uterus will be closed with multiple layers of sutures. The abdominal layers will be closed with absorbable Polyglactin (Vicryl) sutures for the rectus sheath and subcutaneous tissue, and non-absorbable Polypropylene sutures for the skin. A sterile dressing will be applied to protect the wound and promote a clean healing environment, ensuring proper surgical technique, tissue handling, and minimizing post-operative complications.

Intervention type: PROCEDURE
Intervention: Cesarean delivery
Description: The cesarean section will begin with a Pfannenstiel incision above the pubic bone, followed by blunt dissection to separate tissue layers and retracting the rectus muscles for peritoneal cavity access. A transverse or vertical peritoneal incision will expose the uterus, and a transverse incision on the lower uterine segment will be made for delivery. The baby will be delivered, the umbilical cord clamped and cut, and the baby handed to the pediatric team. The placenta will be detached and delivered, and the uterus will be closed with multiple layers of sutures. The abdominal layers will be closed with absorbable Polyglactin (Vicryl) sutures for the rectus sheath and subcutaneous tissue, and non-absorbable Polypropylene sutures for the skin. A sterile dressing will be applied to protect the wound and promote a clean healing environment, ensuring proper surgical technique, tissue handling, and minimizing post-operative complications.
Study: NCT05782218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut
Description: Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
Study: NCT05934799

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel film-coated tablet 75 mg
Description: Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel film-coated tablet 75 mg
Description: Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.

Intervention type: DRUG
Group type: OTHER
Intervention: Plavix® film-coated tablet 75 mg
Description: Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.

Intervention type: DRUG
Group type: OTHER
Intervention: Plavix® film-coated tablet 75 mg
Description: Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
Study: NCT04801316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steady Feet exercise programme
Description: Steady Feet (SF) is a 6-month community-based structured exercise programme aimed at improving physical strength and balance among older adults (aged 60 years and above) who are at high risk of falls.~This exercise programme was developed by Changi General Hospital's physiotherapists and exercise physiologist from evidence found in the literature.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Steady Feet Video
Description: About an hour-long video showcasing the exercise steps of the Steady Feet exercise programme
Study: NCT06424665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZ-AD005
Description: Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT06378658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: light low-fat meal or high fat, high calorie meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: light low-fat meal or high fat, high calorie meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: light low-fat meal or high fat, high calorie meal
Study: NCT05949814

Intervention type: DIAGNOSTIC_TEST
Intervention: acceptability of a PrEP program among HIV-negative MSM and TG
Description: STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability
Study: NCT05561010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of bupivacaine in the knee joint
Description: 25 participants will be allocated to the bupivacaine arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular injection of placebo in the knee joint
Description: 25 participants will be allocated to the placebo arm.
Study: NCT04884776

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome immunity formula
Description: Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Active placebo
Description: Active placebo contains active vitamin
Study: NCT05466708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine combined with dexmedetomidine
Description: Esketamine, injection, 50mg/ bottle, source: hospital pharmacy, production unit: Jiangsu Hengrui Pharmaceutical Co., LTD., validity: 2 years, storage condition: airtight shading, room temperature.~Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Study: NCT05977361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resiting Epidural Catheter
Description: After a UDP has occurred, epidural catheter will be re-sited in a different intervertebral space. Analgesia will be then maintained according to internal protocol, using PIEB (Programmed Intermittent Epidural Bolus) system. Catheter will be left in place for the first 24-36 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Catheter Placement
Description: After a UDP has occurred, an intrathecal catheter will be placed through the dural tap. Analgesia will be then maintained according to internal protocol, using PISB (Programmed Intermittent Subarachnoid Bolus) system. Catheter will be left in place for the first 24-36 hours. During this time, a continuous infusion of sterile saline at a rate of 2 mL/h will be maintained. Before removal, an additional bolus of 10 mL of sterile saline will be administered in the intrathecal catheter.
Study: NCT05466708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine, injection, 0.2mg/ bottle, source: Hospital Pharmacy, manufacturer: Jiangsu Hengrui Pharmaceutical Co., LTD., expiration date: 18 months, storage condition: airtight shading, room temperature.
Study: NCT05551962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue augmentation with CTG
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Sampling of free connective tissue graft from the maxilla tuber area~4. Fixation of the graft to the vestibular flap~5. Suturing the wound tightly
Study: NCT05373771

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care pathway
Description: Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
Study: NCT05551962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation with CM
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly
Study: NCT05187884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darovasertib
Description: Oral Darovasertib 300 mg tablets twice daily
Study: NCT05086913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine smartphone booklets
Description: Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle medicine smartphone app
Description: The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Waitlist control
Description: The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
Study: NCT06207253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Study: NCT05904639

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Decoding Your Diet
Description: We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Decoding Your Diet
Description: We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
Study: NCT05110547

Intervention type: BIOLOGICAL
Intervention: blood collection
Description: 2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.

Intervention type: BIOLOGICAL
Intervention: blood collection
Description: 2 additional 5ml EDTA tubes, with assays for the following markers: 24S and 27 hydroxycholesterol (gas chromatography-mass spectrometry, GC-MS), Neurofilaments (SIMOA), oxydative phosphorylation (OXPHOS) and quantitative measurement of intracellular ATP (ELISA), Very long chain fatty acids (GC-MS), Octanoyl CoA (HPLC), Uric acid, MDA assay (TBAR assay kit), and Lipid panel.
Study: NCT05184296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Membrane Oxygenation (ECMO)
Description: All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
Study: NCT05612295

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-talk
Description: self-talk sessions include: Session 1 \& 2. The concepts, types, and the importance of self-talk will be introduced; Session 3. Researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific instructional scripts for specific sports performance (e.g., running); Session 4. practice of sport-specific instructional self-talk; Session 5. researchers, coaches and the athletes will work together to design syntactically recognizable, concise, and clear sport-specific motivational self-talk scripts for specific sports performances; Session 6. practice of sport-specific motivational self-talk; and Session 7 \& 8. general practice for learned self-talk techniques.
Study: NCT06520202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPRG4 (450 µg/mL)
Description: 1-2 drops of rhPRG4 450 µg/mL solution in both eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPRG4 (450 µg/mL)
Description: 1-2 drops of rhPRG4 450 µg/mL solution in both eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
Study: NCT06447493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment-Spencer's Technique (Modified)
Description: Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment-Spencer's Technique (Modified)
Description: Combination OMT approach utilizing Muscle Energy Technique (MET), Articulatory Technique (ART), and Myofascial Release (MFR). It is a series of direct OMT addressing the barrier of somatic dysfunction (SD) with the goal of restoring neurovascular balance and improved motion of the shoulder girdle and glenohumeral joint. Utilizing these three OMT techniques, the practitioner attempts restoration of glenohumeral joint motion using shoulder extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction, external rotation, internal rotation, and distraction in abduction. The study uses a modified version of the Spencer technique, done in the seated position for patient comfort, as well as adding to the treatment sequence: latissimus dorsi, pectoralis minor-major, serratus anterior, and rhomboid major-minor. Adding these muscles into treatment will help to address and correct sternoclavicular joint SD, acromioclavicular joint SD, and scapular SD.
Study: NCT04917510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: See experimental arm group description